Nadia Omelchenko, MD, Sarcoma Oncology Research Center, Santa Monica, CA, discusses trials combining immune checkpoint inhibitors (ICI) with chemotherapy in patients with advanced soft tissue sarcomas (STC). The Phase I/II SAINT trial (NCT03138161) combines ipilimumab and nivolumab with trabectedin, demonstrating safe and effective results as a first line treatment. A new study, LINNOVATE (NCT05876715), with a similar protocol, is testing ipilimumab and nivolumab with lurbinectedin, an analog of trabectedin with shorter infusion time. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
